Montpellier, France

Mathieu Petremann

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Mathieu Petremann

Introduction

Mathieu Petremann is a notable inventor based in Montpellier, France. He has made significant contributions to the field of medical research, particularly in the prevention of gastrointestinal and colorectal cancer. His innovative work has led to the development of methods and compositions that are beneficial for individuals with pre-cancerous conditions.

Latest Patents

Mathieu Petremann holds a patent for the "Prophylaxis of colorectal and gastrointestinal cancer." This patent outlines methods and compositions that are useful for preventing gastrointestinal and/or colorectal cancer in animals, including humans, who have pre-cancerous adenomatous polyps. The disclosure includes compositions comprising anti-PG antibodies that are suitable for use in these methods. Additionally, it provides methods and compositions for monitoring the efficacy of anti-PG treatment in subjects with pre-cancerous polyps. He has 1 patent to his name.

Career Highlights

Throughout his career, Mathieu has worked with esteemed organizations such as Les Laboratoires Servier and the Institut National de la Santé et de la Recherche Médicale. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Mathieu Petremann has collaborated with notable colleagues, including Leïla Houhou and Dominique Joubert. Their combined expertise has further advanced the research and development of innovative solutions in cancer prevention.

Conclusion

Mathieu Petremann's contributions to medical research, particularly in cancer prevention, highlight his role as an influential inventor. His patent and collaborations reflect his commitment to improving health outcomes for individuals at risk of gastrointestinal and colorectal cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…